Navigation Links
Watson Reaches Settlement with Endo Over Opana® ER
Date:10/7/2010

MORRISTOWN, N.J., Oct. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Endo Pharmaceuticals, Inc. on outstanding patent litigation related to Endo's Opana® ER (Oxymorphone ER) product.  Endo filed its lawsuit on March 4, 2010, following Watson's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for seeking approval to market its product in the 5, 7.5, 10, 15, 20, 30 and 40 mg dosage strengths.

Under terms of the settlement agreement, Endo has granted Watson a royalty-free license to U.S. patents covering Opana® ER.  Watson will have the right to launch its generic equivalent version of the product on September 15, 2012, or earlier under certain circumstances.  Other details of the settlement were not disclosed.  

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations de
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Confirms Azilect® Patent Challenge
2. Watson to Present at the Jefferies 2010 Global SpecPharma & European Healthcare Conference
3. HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada
4. Watson to Present at the Bank of America/Merrill Lynch Global Healthcare Conference
5. Watsons Generic Yasmin® Receives FDA Approval
6. Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
7. Watson Promotes Robert Stewart to Executive Vice President, Global Operations
8. Watson Confirms Renvela® for Oral Suspension Patent Challenge
9. Watson to Host Conference Call and Webcast to Discuss Second Quarter 2010 Earnings
10. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
11. Watsons Generic Prograf® 5 mg Receives FDA Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... ATLANTA , May 1, 2015 At ... May 2-6 in Washington D.C. , ... a solution that enables clinicians to leverage the enormous ... Knife radiosurgery treatments conducted each year – to advance ... "Gamma Knife Registry is a cloud-based solution that allows ...
(Date:5/1/2015)... May 1, 2015 The Institute for Healthcare ... literacy award winners. The IHA Health Literacy Awards aim ... impact on the practice of educating or empowering organizations ... gives awards in three categories: innovative programs, published materials ... Literacy Hero award. In the area of ...
(Date:5/1/2015)... MARLBOROUGH, Mass. , May 1, 2015  Boston ... overview of its continued business momentum and long-term growth ... in New York City . President ... outline the unique opportunities the company has to bring ... into fast growing markets and deliver shareholder value. ...
Breaking Medicine Technology:Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 2Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 3Institute for Healthcare Advancement Announces 2015 Award Winners 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7
... 2011 Reportlinker.com announces that ... is available in its catalogue: ... Drug Safety Strategies and Risk ... clinical success ...
... FRANCISCO, Calif., Oct. 26, 2011 Onyx Pharmaceuticals, ... results from a Bayer HealthCare Pharmaceuticals Phase 3 ... for the treatment of patients with metastatic colorectal ... standard therapies. The trial met its primary endpoint ...
Cached Medicine Technology:Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 2Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 3Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 4Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 5
(Date:5/1/2015)... Ernst & Young (EY) has announced Melanie Rosenthal, ... and Burak Sezen, Co-Founder & CTO of RowdMap, Inc. ... The Year® 2015 Awards in the Ohio Valley Region ... leader in assurance, tax, transaction and advisory services and ... audit companies in the world. The awards program recognizes ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 The Quail Creek ... American Cancer Society. Since 2001, the Quail Creek Relay team ... team host events throughout the year, including their biggest event, ... Golf Ball Drop. , Quail Creek Relay for Life ... battling cancer. Kate Kerwin, fitness director, states, “I was hooked ...
(Date:5/1/2015)... As the sale of legal, recreational cannabis in ... in the industry are looking back with some pride ... report by the ArcView Group , the legal ... nearly $3 billion in combined wholesale and retail sales. ... with the ongoing economic recovery, has led to a ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 The frozen ... with the Hickory Crawdads (NC) and the Myrtle Beach ... have in-stadium concession locations and offer fans discounts at ... of the Hickory Community,” said Luke Shook, co-owner of ... great opportunity and we look forward to enjoying the ...
(Date:5/1/2015)... Pa. (PRWEB) May 01, 2015 Veteran Outreach ... be available to answer questions about VA Vet Centers on ... community. The MVC will be parked in front of the ... conjunction with a free screening of the documentary, “That Which ... impacts of post-traumatic stress disorder. , Please contact Robert Novotney ...
Breaking Medicine News(10 mins):Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2Health News:Quail Creek Country Club’s Relay for Life Team Raised Over $89,000 for American Cancer Society 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 3Health News:sweetFrog Announces Minor League Baseball Partnerships 2
... ... Feb. 3 The National Organization for Rare Disorders (NORD) ... will serve as media and program partners for Rare Disease Day on ... of Rare Disease Day, an event designed to call attention to the ...
... proposed by Max Kleiber in 1932, printed in biology textbooks ... in a 2000 essay in Nature as "extended to all ... wrong. "Actually, it,s two-thirds," says University of Vermont mathematician ... Physical Review Letters helps overturn almost eighty years ...
... , ... Hold Ribbon-Cutting Ceremony with Palms West Chamber of Commerce , ... (PRWEB) February 3, 2010 -- Hugs and Kisses, Inc. will be ... event kicks off with a ribbon-cutting ceremony by the Palms West Chamber of Commerce at 5:00 ...
... pedal-power brings results, study finds , WEDNESDAY, Feb. 3 (HealthDay News) ... who ride bicycles to school are in better shape than those ... of the study examined the results of physical tests and questionnaires ... in 2007 and 2008. , They found that boys who ...
... APR Energy is ... country of Haiti. The supplies will be delivered by four air- freighted shipments and are ... ... of the January 12 earthquake in Haiti, many corporations all over the world have been ...
... , , DUBLIN, Ohio , Feb. 3 ... approved a regular quarterly dividend of $0.175 per share, payable ... 1 . , This marks the 102nd consecutive regular quarterly dividend for ... Jan. 31 . , About Cardinal Health , ...
Cached Medicine News:Health News:Discovery Health and National Organization for Rare Disorders Partner for Second Annual Rare Disease Day With the Premiere of the Special DISEASE DETECTIVES 2Health News:Discovery Health and National Organization for Rare Disorders Partner for Second Annual Rare Disease Day With the Premiere of the Special DISEASE DETECTIVES 3Health News:Discovery Health and National Organization for Rare Disorders Partner for Second Annual Rare Disease Day With the Premiere of the Special DISEASE DETECTIVES 4Health News:Discovery Health and National Organization for Rare Disorders Partner for Second Annual Rare Disease Day With the Premiere of the Special DISEASE DETECTIVES 5Health News:Discovery Health and National Organization for Rare Disorders Partner for Second Annual Rare Disease Day With the Premiere of the Special DISEASE DETECTIVES 6Health News:Spherical cows help to dump metabolism law 2Health News:Spherical cows help to dump metabolism law 3Health News:Hugs and Kisses Open House To Mark The Opening Of Its New Facility 2Health News:APR Energy Launching Haiti Relief Efforts 2Health News:APR Energy Launching Haiti Relief Efforts 3Health News:APR Energy Launching Haiti Relief Efforts 4Health News:Cardinal Health Declares Regular Quarterly Dividend 2
... III, laboratory-grade pure water at a constant ... potable tap water and combine complementary purification ... is easy to operate, reliable, and allows ... a low operating cost., Applications, Glassware ...
... in our largest chest freezer, with 20.7 ... 52,700 samples -- (572) 2" boxes. Like ... utilizes ultra-thin vacuum insulation panel technology to ... Patented Tollesbury Technology improves sample preservation, reduces ...
... III, laboratory-grade pure water at a constant ... potable tap water and combine complementary purification ... is easy to operate, reliable, and allows ... a low operating cost., Applications, Glassware ...
... Premium Model U570 is an ... standards as Innova models. Comparable in ... model uses conventional cascade refrigeration and ... price point. Holds 400 2" boxes. ...
Medicine Products: